Skip to content

Retatrutide

Retatrutide (CAS 2381089-83-2) is a novel triple-agonist peptide targeting the GIP, GLP-1, and glucagon (GCG) receptors simultaneously, with an approximate molecular weight of 4,845 Da. This 39-amino acid synthetic peptide incorporates a C20 fatty diacid-albumin binding moiety that extends elimination half-life to approximately 6 days. By engaging three metabolically complementary class B GPCRs, retatrutide represents an advanced incretin-based research tool for investigating multi-receptor pharmacology in energy homeostasis.

Technical Specifications

Property Value
CAS Number 2381089-83-2
Molecular Formula C₂₂₃H₃₄₃N₄₇O₇₀
Molecular Weight ~4,845 Da
Purity ≥98% (HPLC-verified)
Appearance Lyophilized white powder
Solubility Soluble in aqueous buffers (pH 7.0–8.0)
Storage -20°C (lyophilized), 2–8°C (reconstituted)

Mechanism of Action

Retatrutide is a unimolecular triple agonist designed to activate GIPR, GLP-1R, and the glucagon receptor (GCGR) with a balanced activity profile. At GLP-1R and GIPR, it stimulates cAMP/PKA-dependent insulin secretion and inhibits glucagon release in a glucose-dependent manner, while reducing gastric motility and enhancing satiety signaling. The GCGR activity adds a unique dimension: hepatic GCGR activation promotes lipolysis, fatty acid oxidation, and increased energy expenditure through futile substrate cycling and upregulation of mitochondrial uncoupling proteins. The combined triple-receptor engagement achieves superior weight reduction and glycemic improvement in preclinical models compared to mono- or dual-agonist approaches, with the GCGR component contributing specifically to energy expenditure elevation.

Research Applications

  • Primary: Obesity and metabolic disease research — multi-receptor incretin pharmacology
  • Secondary: Type 2 diabetes models, non-alcoholic steatohepatitis (NASH) research, energy expenditure and thermogenesis studies
  • Model Systems: In vitro (recombinant receptor assays, isolated hepatocytes), in vivo (diet-induced obesity murine models, non-human primate metabolic studies)

Quality Control & Analytical Methods

  • HPLC: ≥98% purity verification at 214/220 nm (C18 reversed-phase column)
  • Mass Spectrometry: ESI-MS for molecular weight confirmation (~4,845 Da)
  • Peptide Content: Amino acid analysis (AAA) for net peptide content determination
  • Endotoxin: <1 EU/mg (LAL assay)
  • TFA Content: <1% (ion chromatography)

Stability & Storage

Condition Stability
-20°C (lyophilized) 24 months
4°C (lyophilized) 6 months
25°C (lyophilized) 1 month
Reconstituted (4°C) 7 days
Reconstituted (-20°C) 30 days

Key Research References

  • Coskun et al. (2022) — LY3437943, a novel triple GIP/GLP-1/glucagon receptor agonist, demonstrates superior weight loss efficacy in preclinical models. Mol Metab. PMID: 35995390
  • Jastreboff et al. (2023) — Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. PMID: 37356055
  • Rosenstock et al. (2023) — Retatrutide (LY3437943) phase 2 trial in type 2 diabetes. Lancet. PMID: 37385282

Source & Purchase

For researchers requiring research-grade RETATRUTIDE with full analytical documentation including HPLC, LC-MS, and Certificate of Analysis, visit the HK Peptides product page for specifications, bulk pricing, and ordering.

View RETATRUTIDE Product →

FAQ

Q: What purity level is standard for Retatrutide? A: HK Peptides supplies Retatrutide at ≥98% purity by HPLC with full COA documentation.

Q: How should Retatrutide be stored for research use? A: Lyophilized Retatrutide should be stored at -20°C. Reconstituted solutions at 4°C for short-term use (up to 7 days).